亚辉龙跌2.15%，成交额5589.34万元，主力资金净流出1299.13万元

Group 1 - The core viewpoint of the news is that Aihuilong's stock has experienced fluctuations, with a recent decline in price and significant changes in trading volume and shareholder structure [1][2]. - As of January 16, Aihuilong's stock price was 15.05 yuan per share, with a market capitalization of 8.599 billion yuan and a trading volume of 55.8934 million yuan [1]. - The company has seen a year-to-date stock price increase of 5.99%, but a decline of 3.77% over the last five trading days [1]. Group 2 - Aihuilong's main business involves the research, production, and sales of in vitro diagnostic instruments and related reagents, with a revenue composition of 58.57% from self-produced reagents (non-COVID products) [1]. - As of September 30, the company reported a revenue of 1.287 billion yuan for the first nine months of 2025, a year-on-year decrease of 7.69%, and a net profit of 60.4209 million yuan, down 72.36% year-on-year [2]. - The company has distributed a total of 693 million yuan in dividends since its A-share listing, with 531 million yuan distributed over the past three years [3].